Form 4: Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Sells Shares

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold a portion of his holdings in common stock through transactions on October 4 and October 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 4, 2024, Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, sold 7,522 shares of common stock at a weighted average price of $27.5109.
• Following this transaction, Mr. Lyssikatos directly owns 1,069,887 shares.
• On October 7, 2024, Mr. Lyssikatos sold an additional 2,707 shares of common stock at a weighted average price of $27.6051.
• After the second transaction, Mr. Lyssikatos directly owns 1,067,180 shares.
• The sales were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• The shares are held by The Lyssikatos Revocable Trust 12/15/2011, for which the Reporting Person serves as trustee.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, reporting the sale of shares by a company insider. The sentiment is neutral as it simply reflects transactions and doesn't convey any explicit positive or negative outlook.

Industry Context

Insider sales are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's valuation and future prospects. Sales under a pre-arranged 10b5-1 trading plan are generally viewed as less indicative of management's current sentiment, as the plans are established in advance to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sales by a key officer may cause some investors to re-evaluate their positions in the company.

Key Dates